Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
Active Ingredient B
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
Phase III
Clinical Site 1 Clinical Site 2 |
| gptkbp:community_service |
available
biomarker E biomarker_F |
| gptkbp:contraindication |
anemia
vomiting diarrhea liver disease pregnancy |
| gptkbp:developedBy |
Pharmaceutical Company Y
|
| gptkbp:dosageForm |
oral
intravenous |
| gptkbp:drugInterdiction |
targeted therapy
antineoplastic agent half-life 24 hours |
| gptkbp:formulation |
tablet
injection |
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
CancerDrugX
|
| gptkbp:impact |
1 year
6 months |
| gptkbp:interactsWith |
Drug C
Drug D |
| gptkbp:is_monitored_by |
liver function tests
blood cell counts |
| gptkbp:lastProduced |
2018-06-15
|
| gptkbp:mandates |
breast cancer
non-small cell lung cancer leukemia |
| gptkbp:manufacturer |
Manufacturer Z
|
| gptkbp:marketedAs |
Brand Name A
|
| gptkbp:offers |
$10,000 per month
|
| gptkbp:patentExpiration |
2025-12-31
|
| gptkbp:provides |
ASCO guidelines
NCCN_guidelines |
| gptkbp:researchAreas |
ongoing studies
|
| gptkbp:route |
IV
oral |
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea hair loss |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
inhibits cell division
|
| gptkbp:usedFor |
treating cancer
|